[Code of Federal Regulations]
[Title 21, Volume 1]
[Revised as of April 1, 2007]
From the U.S. Government Printing Office via GPO Access
[CITE: 21CFR50.52]
[Page 288-289]
TITLE 21--FOOD AND DRUGS
CHAPTER I--FOOD AND DRUG ADMINISTRATION,
DEPARTMENT OF HEALTH AND HUMAN SERVICES
PART 50_PROTECTION OF HUMAN SUBJECTS--Table of Contents
Subpart D_Additional Safeguards for Children in Clinical Investigations
Sec. 50.52 Clinical investigations involving greater than minimal risk but
presenting the prospect of direct benefit to individual subjects.
Any clinical investigation within the scope described in Sec. Sec.
50.1 and 56.101 of this chapter in which more than minimal risk to
children is presented by an intervention or procedure that holds
[[Page 289]]
out the prospect of direct benefit for the individual subject, or by a
monitoring procedure that is likely to contribute to the subject's well-
being, may involve children as subjects only if the IRB finds and
documents that:
(a) The risk is justified by the anticipated benefit to the
subjects;
(b) The relation of the anticipated benefit to the risk is at least
as favorable to the subjects as that presented by available alternative
approaches; and
(c) Adequate provisions are made for soliciting the assent of the
children and permission of their parents or guardians as set forth in
Sec. 50.55.
http://a257.g.akamaitech.net/7/257/2422/26mar20071500/edocket.access.
gpo.gov/cfr_2007/aprqtr/21cfr50.52.htm